{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-23-000074","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.494632+00:00","generated_at":"2026-06-11T22:16:55.617450+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Summit Therapeutics Q2 net loss $14.7M; cash at $215M; HARMONi trials underway","bullets":["Net loss for Q2 2023 was $14.7M vs $16.8M YoY; six-month net loss $557.1M including $520.9M one-time IPR&D charge for ivonescimab license.","Cash, equivalents, and short-term investments at June 30, 2023 totaled $215M, down from $648.6M at Dec 31, 2022; notes payable $100M due Sept 2024.","First US patient dosed in Phase III HARMONi trial (ivonescimab + chemo in EGFR-mutant NSCLC); HARMONi-3 trial in first-line squamous NSCLC to begin H2 2023.","Phase II data from Akeso's AK112-201 trial: median PFS 11 months, ORR 67% in first-line squamous NSCLC; presented at ASCO 2023.","Collaboration license paid $500M upfront to Akeso; Akeso eligible for up to $4.5B in milestones plus low double-digit royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-23-000074","json":"https://secwatch.observer/filing/0001599298-23-000074.json","markdown":"https://secwatch.observer/filing/0001599298-23-000074.md","text":"https://secwatch.observer/filing/0001599298-23-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929823000074/0001599298-23-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929823000074/smmt-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:16:55.617450+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01614b658982386c20ff0792b08fc92487192bdd","claim":"Summit Therapeutics Inc. reported the second quarter ended June 30, 2023 results: net income $14.7 million.","evidence_excerpt":"Net loss for the three and six months ended June 30, 2023 was $14.7 million and $557.1 million, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929823000074/0001599298-23-000074-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"$14.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"350304edc48a68ea0738be46a41268f5ecf7c774","claim":"Summit Therapeutics Inc. reported the six months ended June 30, 2023 results: net income $557.1 million.","evidence_excerpt":"Net loss for the three and six months ended June 30, 2023 was $14.7 million and $557.1 million, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929823000074/0001599298-23-000074-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Net income","value":"$557.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}